Nasdaq GlobeNewswire

Oxford Immunotec Reports Third Quarter 2017 Financial Results

Del
  • Third quarter revenue of $30.4 million, an increase of 17% compared to prior year period
  • Continued growth from both the Tuberculosis (TB) and Tick-borne disease franchises, with double-digit revenue growth in all three geographies served
  • Gross margin improved by 450 basis points on a sequential basis, driven by strong progress in TB margins

OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced third quarter 2017 financial results.

"We are pleased to report another strong quarter, with solid growth across both franchises and all three geographies served," said Dr. Peter Wrighton-Smith, Chief Executive Officer of Oxford Immunotec. "As we move forward through the remainder of the year and into 2018, we will continue to focus on driving revenue growth and progressing the company towards profitability."

By revenue type, total revenues were, in millions:

  Three Months Ended September 30,
   2017    2016   Percent
Change
           
Product $   12.0   $   9.7   24 %
Service     18.4       16.4   12 %
Total Revenue $   30.4   $   26.1   17 %

By indication, total revenues were, in millions:

  Three Months Ended September 30,
   2017    2016   Percent
Change
           
Tuberculosis $   24.4   $   22.0   11 %
Tick-Borne Disease and Other     6.0       4.1   45 %
Total Revenue $   30.4   $   26.1   17 %
           

By geography, total revenues were, in millions:

  Three Months Ended September 30,
          Percent Change
   2017    2016   As Reported   Constant
Currency 
(1)
               
United States $   18.8   $   16.2   16 %   16 %
Europe & ROW   2.2       1.7   26 %   22 %
Asia     9.4       8.2   15 %   18 %
Total Revenue $   30.4   $    26.1   17 %   17 %
               

(1) Changes in revenue include the impact of changes in foreign currency exchange rates. We use the non-GAAP financial measure "constant currency basis" in our filings to show changes in our revenue without giving effect to period-to-period currency fluctuations. We consider the use of a period over period revenue comparison on a constant currency basis to be helpful to investors, as it provides a revenue growth measure free of positive or negative volatility due to currency fluctuations.

Third Quarter 2017 Financial Results

Revenue for the third quarter of 2017 was $30.4 million, representing 17% growth over third quarter 2016 revenue of $26.1 million. On a constant currency basis, revenue growth was also 17% versus the prior year period. Tuberculosis revenue for the third quarter of $24.4 million increased 11% over the prior year period.

2017 third quarter product revenue was $12.0 million, representing a 24% increase from product revenue of $9.7 million in the third quarter of 2016. The increase was primarily driven by sales of tick-borne disease kits, as well as growth in Asia and Europe & ROW. Service revenue for the third quarter of 2017 was $18.4 million, up 12% from 2016 third quarter revenue of $16.4 million. The increase in service revenue was primarily driven by strong growth in our tick-borne disease business, as well as tuberculosis volume increases in the United States.

United States revenue was $18.8 million in the third quarter of 2017, representing 16% growth over revenue of $16.2 million in the prior year period. The increase was due to growth in our tuberculosis and tick-borne disease businesses.

Europe & ROW revenue was $2.2 million in the third quarter of 2017, representing a 26% increase compared to the third quarter of 2016. On a constant currency basis, Europe & ROW increased 22% versus the third quarter of 2016. The increase was primarily due to tuberculosis growth in the UK and continental European markets, as well as sales of tick-borne disease kits.

Asia revenue was $9.4 million in the third quarter of 2017, representing an increase of 15% over 2016 third quarter revenue of $8.2 million. On a constant currency basis, Asia increased 18% versus the third quarter of 2016. The increase was primarily due to the timing of orders and higher sales in South Korea.

Gross profit for the third quarter of 2017 was $17.3 million, an increase of $2.7 million over gross profit of $14.6 million in the same period of 2016. Gross margin was 56.7%, an increase of 80 basis points from gross margin of 55.9% in the third quarter of 2016. The third quarter gross margin performance reflects lower royalty expenses due to the June 2017 Statens Serum Institut settlement, an underlying improvement in TB margins, and favorable mix, offset by higher volumes in our tick-borne disease business, which carries lower gross margins, as well as some early infrastructure investments necessary to meet future growth.

Operating expenses were $32.5 million in the third quarter of 2017, an increase of $13.6 million compared to $18.9 million in the same period last year. The increase in operating expenses was largely due to the inclusion of a one-time non-cash impairment charge of $11.1 million to write-off certain intangible assets acquired in conjunction with the 2016 acquisition of Imugen, as well as expenses related to our BLA submissions and ongoing patent litigation. In the third quarter, we also recorded a credit of $880,000 related to the change in fair value of contingent consideration associated with the acquisition of Immunetics.

Net loss for the third quarter of 2017 was $16.9 million, or $0.70 per share, compared to $4.0 million, or $0.18 per share, in the third quarter of 2016. Net loss per share was based on 24,123,574 and 22,365,349 weighted average ordinary shares outstanding for the third quarters of 2017 and 2016, respectively.

EBITDA for the third quarter was $(14.7) million compared to $(3.0) million in the third quarter of 2016. Adjusted EBITDA for the third quarter of 2017 was $(2.5) million compared to $(2.2) million in the same period in 2016. Both EBITDA and Adjusted EBITDA are non-GAAP measures.

Business Outlook

We expect to report revenue of between $25.4 and $26.4 million for the fourth quarter of 2017.

We now expect to report full year 2017 revenue of between $103.5 and $104.5 million, representing 20% - 21% year-over-year growth. We expect revenue to increase approximately 21% to 22% for the year using constant exchange rates. This compares to prior revenue guidance of between $103 and $106 million.

Conference Call

Oxford Immunotec will host a conference call on Tuesday, October 31, 2017 at 8:00 a.m. Eastern Time to discuss its third quarter 2017 financial results. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 99539511 approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately 60 days.

About Oxford Immunotec

Oxford Immunotec Global PLC is a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions.  The Company's first product is the T-SPOT®.TB test, which is used to test for tuberculosis infection.  The T-SPOT.TB test has been approved for sale in over 50 countries, including the United States, where it has received pre-market approval from the Food and Drug Administration, Europe, where it has obtained a CE mark, as well as Japan and China.  The Company's second product line is a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics.  Also obtained through these acquisitions is the Company's third product line focused on screening for Babesia in donated blood, for which the Company is currently seeking FDA licensure.  The Company's fourth product line is focused on the transplantation market.  The Company is headquartered near Oxford, U.K. and in Marlborough, Mass.  Additional information can be found at www.oxfordimmunotec.com.

T-SPOT and the Oxford Immunotec logo are trademarks of Oxford Immunotec Ltd.  Immunetics is a trademark of Immunetics, Inc.

Forward-Looking Statements
This release contains forward-looking statements that involve risks and uncertainties, including statements about our anticipated plans, objectives, intentions, including effects on future financial and operating results, prospects for sales of our products and other statements that are not historical facts. The forward-looking statements in this release are based on current expectations, assumptions and data available as of the date of this release and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements, including but not limited to: decisions by regulatory authorities, hospitals and other health care institutions, laboratories, physicians, patients and third party payers that could affect the Company's business and prospects; as well as our ability to expeditiously and successfully expand our sales and distribution networks. The risks included above are not exhaustive. Other factors that could adversely affect our business and prospects are described under the "Risk Factors" section in our filings with the Securities and Exchange Commission ("SEC"). Our filings are available for free by visiting the investor section of our website, www.oxfordimmunotec.com, or the SEC's website, www.sec.gov.

Investors should give careful consideration to these risks and uncertainties. Forward-looking statements contained herein are based on current expectations and assumptions and currently available data and are neither predictions nor guarantees of future events or performance. You should not place undue reliance on forward-looking statements contained herein, which speak only as of the date of this release. We do not undertake to update or revise any forward-looking statements after they are made, whether as a result of new information, future events, or otherwise, except as required by applicable law.

CONTACTS:

For Media and Investor Inquiries: 
Karen Koski
Head of Strategy and Investor Relations
Oxford Immunotec
Tel: +1 (508) 556-1377
kkoski@oxfordimmunotec.com

Oxford Immunotec Global PLC
Condensed consolidated statements of operations
(unaudited)
 
    Three months ended September 30,   Nine months ended September 30,
(in thousands, except share and per share data)     2017       2016       2017       2016  
Revenue                
Product   $   12,000     $   9,713     $   30,808     $   27,144  
Service       18,429         16,396         47,246         35,229  
Total revenue       30,429         26,109         78,054         62,373  
Cost of revenue                
Product       4,027         3,616         11,366         10,421  
Service       9,141         7,887         24,791         17,853  
Total cost of revenue       13,168         11,503         36,157         28,274  
Gross profit       17,261         14,606       41,897       34,099  
Operating expenses:                
Research and development       4,467         3,532         12,220         9,837  
Sales and marketing       9,493         8,794         29,174         26,665  
General and administrative       8,141         6,466         23,007         16,200  
Change in fair value of contingent purchase price consideration       (880 )       60         (3,475 )       172  
Intangible assets impairment charges       11,064         -         11,064         -  
Settlement expense       196         -         9,831         -  
Total operating expenses       32,481         18,852         81,821         52,874  
Loss from operations       (15,220 )       (4,246 )       (39,924 )       (18,775 )
Other income (expense):                
Interest expense, net       (781 )       (54 )       (2,411 )       (88 )
Foreign exchange (losses) gains       (624 )       470         (1,277 )       1,707  
Other expense       -         (106 )       (262 )       (243 )
Loss before income taxes       (16,625 )       (3,936 )       (43,874 )       (17,399 )
Income tax (expense) benefit       (222 )       (60 )       2,189         (92 )
Net loss   $   (16,847 )   $   (3,996 )   $   (41,685 )   $   (17,491 )
                 
Net loss per ordinary share-basic and diluted   $   (0.70 )   $   (0.18 )   $   (1.80 )   $   (0.78 )
                 
Weighted-average shares used to compute net loss per ordinary share-basic and diluted       24,123,574         22,365,349         23,159,986         22,333,911  

Reconciliation of net loss to Adjusted EBITDA (1)
(unaudited)
 
    Three months ended September 30,   Nine months ended September 30,
(in thousands)     2017       2016       2017       2016  
Net loss   $   (16,847 )   $   (3,996 )   $   (41,685 )   $   (17,491 )
Income tax expense (benefit)       222         60         (2,189 )       92  
Interest expense, net       641         54         1,982         88  
Depreciation and amortization of intangible assets       1,122         862         3,115         2,067  
Accretion and amortization of loan fees       140         -         429         -  
EBITDA       (14,722 )       (3,020 )     (38,348 )       (15,244 )
                 
Reconciling items:                
Share-based compensation expense       1,506         1,368         4,266         3,827  
Unrealized exchange losses (gains)       333         (572 )       614         (1,990 )
Change in fair value of contingent purchase price consideration       (880 )       60         (3,475 )       172  
Intangible assets impairment charges       11,064         -         11,064         -  
Settlement expense       196         -         9,831         -  
Adjusted EBITDA   $   (2,503 )   $   (2,164 )   $   (16,048 )   $   (13,235 )

(1) EBITDA and Adjusted EBITDA are non-GAAP measures that we calculate as net loss, adjusted for the impact of earnings or charges resulting from matters that we consider not to be indicative of our ongoing operations. We believe that these measures provide useful information to investors in understanding and evaluating our operating results in the same manner as our management and Board of Directors. Our presentation of these measures is not made in accordance with U.S. GAAP, and our computation of these measures may vary from others in the industry. Our use of these measures has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our results as reported under U.S. GAAP.

The above table presents a reconciliation of net loss, the most comparable U.S. GAAP measure, to EBITDA and Adjusted EBITDA for each of the periods indicated.

Oxford Immunotec Global PLC
Condensed consolidated balance sheets
(unaudited)
 
    September 30,   December 31,
(in thousands, except share and per share data)     2017       2016  
Assets        
Current assets:        
Cash and cash equivalents   $   67,743     $   59,110  
Accounts receivable, net       21,652         13,265  
Inventory, net       9,174         7,437  
Prepaid expenses and other assets       3,147         2,390  
       
Total current assets     101,716         82,202  
Restricted cash, non-current       200         200  
Property and equipment, net       8,927         7,793  
In-process research and development       6,970         16,170  
Goodwill       3,967         3,822  
Other intangible assets, net       8,296         11,017  
Deferred tax asset       6,725         2,630  
Other assets       190         178  
         
Total assets   $ 136,991     $ 124,012  
         
Liabilities and shareholders' equity        
Current liabilities:        
Accounts payable   $   3,141     $   3,201  
Accrued liabilities       15,563         14,282  
Settlement liability       2,396         -  
Contingent purchase price consideration       -         882  
Deferred income       345         41  
Current portion of loans payable       89         84  
         
Total current liabilities       21,534         18,490  
Long-term portion of loans payable       29,787         29,601  
Settlement liability       7,930         -  
Contingent purchase price consideration       -         2,593  
Other liabilities       364         364  
         
Total liabilities       59,615         51,048  
         
Shareholders' equity:        
Ordinary shares, £0.006705 nominal value; 36,183,293 shares authorized at September 30, 2017 and December 31, 2016, and 25,596,345 and 22,635,431 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively       269         243  
Additional paid-in capital     292,959       249,128  
Accumulated deficit     (210,341 )     (168,656 )
Accumulated other comprehensive loss       (5,511 )       (7,751 )
         
Total shareholders' equity       77,376         72,964  
         
Total liabilities and shareholders' equity   $ 136,991     $ 124,012  




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Oxford Immunotec via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Pinnacle Studio 22 Ultimate Amps Up Video Editing with New Pro-inspired Features14.8.2018 15:11Pressemelding

New Three- and Four-Point Editing, Color Grading, and MultiCam Capture Lite deliver advanced video editing options to bring your videos even closer to pro OTTAWA, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Introducing Pinnacle Studio™ 22 Ultimate, Pinnacle’s flagship video editing software that offers powerful features, precise editing controls, and premium effects to create eye-catching video projects with professional flair. With new Three- and Four-Point Editing, Color Grading, dynamic Split Screen videos, MultiCam Capture Lite, and more, Pinnacle Studio 22 Ultimate gives users a complete collection of pro-inspired features to express their unique vision and achieve stunning results. “Pinnacle Studio Ultimate is the go-to choice for users looking for true creative control and a sophisticated editing experience from a consumer video editor,” said Michel Yavercovski, Senior Director of Product Management for Pinnacle. “With the latest version, we’re pushing this even further with a pro-inspire

Keesal, Young & Logan and Mitratech Announce TAP Workflow Automation Partnership with the Launch of Keesal Propulsion Labs14.8.2018 15:02Pressemelding

NEW YORK, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Keesal, Young & Logan (KYL) and Mitratech announced today the TAP Workflow Automation partnership to help a greater number of legal professionals quickly implement standardization and compliance across a wide range of legal processes, starting with KYL’s own clients. But it doesn’t stop there. The partnership has resulted in the launch of Keesal Propulsion Labs (KPL) designed to position KYL as an extension of their clients’ teams — helping them to expand and connect their tech stack to solve complex legal and business process challenges. “The goal of KPL is to break down the walls between solution providers, law firms and clients so they can operate as one unit and transform legal operations into a center of excellence that drives innovation across the entire organization,” said Justin Hectus, CIO/CISO at KYL. “By creating cross-ecosystem collaboration, we are uniting people, processes, and compliance, to help mitigate risk and position the

Meltwater launches data science platform Fairhair.ai to tame real-time market signals found in world’s online data14.8.2018 15:00Pressemelding

AI-powered platform democratises analytics of forward-looking indicators based on insights from the outside, known as Outside Insight SAN FRANCISCO, Aug. 14, 2018 (GLOBE NEWSWIRE) -- In the quest to become data-driven, companies are increasingly investing in Business Intelligence software to gain a competitive advantage. Yet the insights generated by those tools are mostly fuelled by data from within a company’s walls, instead of the real-time market signals found externally online – from consumer opinions to corporate filings. This outside data can unlock key indicators about an industry or competitor, but harnessing the volume and variety of global data is a time-intensive task. And although advances in artificial intelligence have made it easier to capture and analyse this data to create powerful insights, most commercial AI tools are one-size-fits-all models with limited capabilities. That’s why Meltwater – a pioneer of media intelligence and curator of the world’s most diverse col

Gratomic Provides Update on Perpetuus Graphene Development Program14.8.2018 14:00Pressemelding

TORONTO, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Gratomic Inc. (“GRAT” or the “Company”) (TSX-V: GRAT) (FRANKFURT:CB81, WKN:A2JAP3). Gratomic, is pleased to provide an update on its previously announced Graphene development program primarily targeted towards elastomer and polymer tire markets, launched with its European partner, Perpetuus Carbon Technologies Limited (“Perpetuus”), a wholly owned subsidiary of Perpetuus Advanced Materials. As disclosed by Gratomic on April 22, 2018, Perpetuus and Gratomic executed a letter of collaboration pursuant to which Perpetuus undertook to build three specialized process tooling chambers (“Chambers”) to be used solely for processing Graphite from Gratomic’s Aukam Graphite mine in Namibia. The first of such Chambers has passed the testing phase and is ready to process the Aukam sourced Graphite, the second Chamber is presently under construction with the third to follow immediately thereafter. Photos accompanying this announcement are available at http:

CrownBio Expands Genetically Engineered Model Selection Via Strategic Alliance with Shanghai Model Organisms Center (SMOC)14.8.2018 14:00Pressemelding

Alliance enables researchers to access thousands of GEMMs SAN DIEGO, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has entered a strategic alliance with Shanghai Model Organisms Center (SMOC) to exclusively license and commercialize SMOC’s comprehensive collection of genetically engineered models, including proprietary transgenic and reporter models for oncology, cardiovascular and immunology research. SMOC leverages expertise in several gene editing technologies to develop conventional knockout (KO), conditional KO, transgenic knock-in and humanized models. These capabilities are now exclusively available to CrownBio’s international clients for custom model generation, breeding, IVF, rapid expansion and re-derivation capabilities. “The strategic alliance with SMOC helps CrownBio become a leading global provid

Paper in Scientific Reports Highlights Ability of 4D Pharma’s MRx0004 to Protect Against Airway Inflammation in Severe Asthma14.8.2018 08:00Pressemelding

Data suggest that MRx0004 is a promising next-generation therapeutic for management of asthma LEEDS, United Kingdom, Aug. 14, 2018 (GLOBE NEWSWIRE) -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, today announces the publication of a paper demonstrating that MRx0004, a live biotherapeutic derived from the human gut microbiome, can protect against airway inflammation by reducing both neutrophilic and eosinophilic infiltration in a mouse model of severe asthma. The paper “Bifidobacterium breve MRx0004 protects against airway inflammation in a severe asthma model by suppressing both neutrophil and eosinophil lung infiltration” (Raftis et al.) is published in the Nature Publishing Group journal Scientific Reports . Asthma is a phenotypically heterogeneous disease. Between 5-10 % of asthma patients have a severe form of the disease which is refractory to steroid treatment and whose symptoms cannot be controlled despite the application o

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom